Smartlab Europe

Wasdell Group strengthens offering with Honeywood acquisition

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.
- Advertisement -

The Wasdell Group (Wasdell), a leading outsourcing partner for companies in the pharmaceutical industry, has announced its acquisition of Honeywood Limited, a specialist manufacturer and packager located in Northampton, UK.

The acquisition will strengthen and expand Wasdell’s manufacturing and packaging capacity in the UK to support the company’s growing client portfolio.

Commenting on the announcement, Vincent Dunne, CEO of The Wasdell Group said: “We are excited to announce the acquisition of Honeywood into the Wasdell Group. Expanding our current offering is the latest step in our ongoing strategic growth plans to meet rising demand for outsourced pharmaceutical services.

“By increasing our capacity and service offerings here in the UK, we will be able better service our growing client base in the US as they look to Wasdell to provide a fully outsourced supply chain for their products within Europe.”

Bringing additional experience into the Wasdell Group, Honeywood has operated as a contract manufacturer to the pharmaceutical and healthcare industries for over 20 years.

Martin Tedham, Chairman of the Wasdell Group added: “Honeywood caught our attention due to its synergies with the existing Wasdell operations. In particular, its oral liquid manufacturing capabilities will allow us to instantly increase capacity beyond our Newcastle upon Tyne facilty to meet customer requests.

“Customers will benefit from expanded services, capacity and continuity. Honeywood’s operations will easily integrate into our current operations, and we are looking forward to collaborating with the current owners and staff moving forward.”

The acquired site will also help to maintain the group’s additional portfolio of nutraceutical clients.

This news follows the recent announcement of the group’s European headquarters in Dundalk, Ireland, a custom-built state-of-the-art facility that is set to open its doors later this month.

Honeywood Limited was advised on this transaction by Wilson Browne Solicitors. For more information on Wasdell and its solutions, visit http://www.wasdell.co.uk

About Wasdell Group
The Wasdell Group provides the pharmaceutical and nutraceutical industries with solutions to a range of outsourcing requirements. Established in 1971, with multiple sites in Europe, employing 1000 people, the group offers an impressive range of technical, manufacturing, packaging and storage and distribution services. For more information on Wasdell and its solutions, visit http://www.wasdell.co.uk

Latest stories

Related stories

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

White House-Big Pharma Tariff and Pricing Deals in 2026

In early 2026, the White House struck a series of tariff and pricing deals with major pharma firms, linking lower prices for GLP‑1 and other drugs to tariff relief and new distribution channels. Explore how these arrangements are reshaping U.S. pharma pricing, access and global spillovers.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »